Cost–risk analysis of available cervix cancer vaccine: Situation analysis from Thailand

Abstract

1. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev 2017;26:444‐57. 2. Harper DM, DeMars LR. HPV vaccines – A review of the first decade. Gynecol Oncol 2017;146:196‐204. 3. Wiwanitkit V. Screening for cervical cancer, results from Thailand. Asian Pac J Cancer Prev 2006;7:329‐30. 4. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of cervarix and gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18‐45 years. Hum Vaccin 2009;5:705‐19. 5. Draper E, Bissett SL, Howell‐Jones R, Waight P, Soldan K, Jit M, et al. A randomized, observer‐blinded immunogenicity trial of cervarix(®) and gardasil(®) human papillomavirus vaccines in 12‐15 year old girls. PLoS One 2013;8:e61825. 6. Song X, Mao F, Zhou Z, Zhao Q, Fang Y. Health economic evaluation of human papillomavirus vaccines in the developing countries: Systematic reviews. Zhonghua Yu Fang Yi Xue Za Zhi 2016;50:85‐90. 7. Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol 2016;28:4‐10. 8. Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. J Am Acad Dermatol 2015;73:759‐67. 9. Haskins‐Coulter T, Southern J, Andrews N, Miller E. Reactogenicity of cervarix and gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females. Hum Vaccin Immunother 2017;13:1‐9.